Skip to main content
. 2024 May 17;28(1):332. doi: 10.3892/ol.2024.14465

Figure 3.

Figure 3.

Tumor marker levels and clinical events during Dur/Tre treatment. Dur/Tre, tremelimumab plus durvalumab; Dur, durvalumab; CR, complete response; RECIST, Response Evaluation Criteria in Solid Tumors; AFP, α-fetoprotein; AFP-L3, α-fetoprotein L3 isoform; DCP, des-γ-carboxy prothrombin; DKA, diabetic ketoacidosis.